<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04842760</url>
  </required_header>
  <id_info>
    <org_study_id>PI2021_843_0039</org_study_id>
    <nct_id>NCT04842760</nct_id>
  </id_info>
  <brief_title>PLATELET Function Assay With Flow Imaging on ImageSTREAM Cytometer</brief_title>
  <acronym>PLATELETSTREAM</acronym>
  <official_title>PLATELET Function Assay With Flow Imaging on ImageSTREAM Cytometer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Platelets are essential blood elements to maintain hemostasis. Quantitative or qualitative&#xD;
      defects can be responsible of hemorrhagic (platelet disorders) or thrombotic (heparin induced&#xD;
      thrombocytopenia [HIT]) troubles. Diagnosis of these pathologies is sometimes urgent and&#xD;
      consists in delicate platelet functional assays that are mostly made in expert centers. These&#xD;
      platelets functional assays measure platelets activation and/or aggregation in response to&#xD;
      diverse inductors and may lack sensitivity. The investigators would like to propose a new&#xD;
      diagnostic tool with the use of imaging flow cytometry which provides much more information&#xD;
      than classic cytometer on cell morphology thanks to images collected by the optical channel&#xD;
      of the ImageStream cytometer. The use of this cytometer offers an innovative approach.&#xD;
&#xD;
      This study is a monocentric prospective and non-interventional study. The investigators will&#xD;
      analyze patient samples with the ImageStream cytometer and reference laboratory tests (light&#xD;
      transmission aggregometry and serotonin release assay) in parallel and compare results from&#xD;
      the different techniques. This new diagnostic technique will demonstrate a non-inferiority&#xD;
      diagnosis compared to reference tests and maybe a better sensibility.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Concordance between ImageStream cytometer and reference laboratory tests for platelet disorders diagnosis</measure>
    <time_frame>12 months</time_frame>
    <description>platelet disorders reference laboratory tests are light transmission aggregometry and serotonin release assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concordance between ImageStream cytometer and reference laboratory tests for HIT diagnosis</measure>
    <time_frame>12 months</time_frame>
    <description>reference laboratory tests are light transmission aggregometry and serotonin release assay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterization of platelet morphology with ImageStream</measure>
    <time_frame>12 months</time_frame>
    <description>Analyses of data provided by the ImageStream system on platelets and platelets aggregates</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Platelet Disorder</condition>
  <condition>Heparin-induced Thrombocytopenia</condition>
  <condition>Platelet Activation</condition>
  <condition>Platelet Aggregation</condition>
  <arm_group>
    <arm_group_label>No platelet disorders or no HIT</arm_group_label>
    <description>Patients without platelet disorders or without HIT, without anti-PF4/H antibodies, without anti-aggregant treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIT patients with anti-PF4/H antibodies</arm_group_label>
    <description>patients with anti-PF4/H antibodies but for whom HIT was ruled out.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>platelet dysfunction or HIT</arm_group_label>
    <description>Patients with platelet dysfunction or suffering from HIT</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Male or female patient for whom a blood test was prescribed in a context of diagnosis of&#xD;
        platelet dysfunction or HIT.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male or female patient for whom a blood test was prescribed in a context of diagnosis&#xD;
             of platelet dysfunction or HIT&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  minor patients&#xD;
&#xD;
          -  patients who have opposed the use of their personal data for research work.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Maïlys LE GUYADER, MD</last_name>
    <phone>03.22.08.70.00</phone>
    <email>leguyader.mailys@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80480</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Maïlys LE GUYADER, MD</last_name>
      <phone>03.22.08.70.00</phone>
      <email>leguyader.mailys@chu-amiens.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 7, 2021</study_first_submitted>
  <study_first_submitted_qc>April 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2021</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Platelet Disorder</keyword>
  <keyword>Heparin-induced Thrombocytopenia</keyword>
  <keyword>ImageStream cytometer</keyword>
  <keyword>Platelet activation</keyword>
  <keyword>Platelet aggregation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Blood Platelet Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

